Teva Stakes OTC Claim With P&G Joint Venture
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva is making a big push into OTCs, announcing a joint venture with Procter & Gamble to combine OTC businesses outside North America.
You may also be interested in...
Chief Executive Change At Teva Illustrates Diversification Emphasis At Major Generic Drug Makers
Most of the top 20 generic drug makers are subsidiaries of diversified pharmas or smaller generics-only plays based in the Far East. But diversification, although long a goal, is now urgent for the three major independent generic firms – Teva, Mylan and Watson.
Former “String Of Pearls” Strategist Tabbed To Lead Teva’s Continuing Diversification
Jeremy Levin, who left Bristol-Myers Squibb on Jan. 1, will succeed outgoing Teva CEO Shlomo Yanai in May, as the Israeli generics giant seeks to increase its emphasis on branded drugs.
Teva Buys Japanese Generics Company For $460 Mil.
Teva Pharmaceutical Industries Ltd. announced May 16 that it is acquiring more than half of Japan's third largest generic drugmaker and extending an offer to purchase the remaining portion of the company